Previous 10 | Next 10 |
2023-07-18 17:26:50 ET Gainers: Ribbon Communications ( NASDAQ: RBBN ) +7% . Terns Pharmaceuticals ( TERN ) +3% . Arrival ( ARVL ) +3% . EyePoint Pharmaceuticals ( EYPT ) +3% . Lyra Therapeutics ( LYRA ) +3% . ...
FOSTER CITY, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including o...
2023-06-27 13:14:58 ET Gainers: AC Immune ( ACIU ) +48% . Tivic Health Systems ( TIVC ) +47% . The Arena Group Holdings ( AREN ) +27% . Ispire Technology ( ISPR ) +21% . Enovix Corporation ( ENVX ) +20% . Advanced Health Inte...
2023-06-27 13:03:37 ET Biopharmaceutical firms focused on liver diseases trended lower Tuesday after pharma giant Eli Lilly ( NYSE: LLY ) announced data highlighting the potential of its weight loss candidate retatrutide in obese patients with excess liver fat. The condition kno...
2023-06-26 17:20:36 ET Gainers: Terns Pharmaceuticals ( NASDAQ: TERN ) +7% . Savara ( SVRA ) +5% . Nkarta ( NKTX ) +5% . COMPASS Pathways ( CMPS ) +3% . Matterport ( MTTR ) +2% . Losers: Adicet ( ACET ...
TERN-601 significantly improved glucose tolerance, suppressed food intake and slowed gastric emptying in a preclinical transgenic mouse model Company to participate in upcoming Piper Sandler Inaugural Obesity Investor Day on June 28 th Company to host webinar detailing T...
FOSTER CITY, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including o...
FOSTER CITY, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including o...
2023-06-01 18:47:13 ET Summary Terns Pharmaceuticals has a promising pipeline with potential best-in-class therapies for obesity and NASH. Upcoming data readouts for TERN-601 and TERN-501 could unlock value, with positive outcomes expected for both binary events. Terns is well...
2023-05-31 13:08:31 ET Roth MKM has started coverage of Terns Pharmaceuticals ( NASDAQ: TERN ) with a buy rating as it sees potential with the company's assets for oncology, nonalcoholic steatohepatitis ( NASH ), and obesity. The firm has a $23 price target (~117% upside bas...
News, Short Squeeze, Breakout and More Instantly...
Terns Pharmaceuticals Inc. Company Name:
TERN Stock Symbol:
NASDAQ Market:
Terns Pharmaceuticals Inc. Website:
2024-07-20 09:30:00 ET Eli Lilly and Novo Nordisk are, for now, the undisputed champions of the market for weight-loss medicines. Thanks to the outrageous popularity of Lilly's drug Zepbound and Novo's product Wegovy, the biggest contest of the moment will go to whoever can ramp up ...
2024-07-17 00:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
FOSTER CITY, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including o...